Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete
Revatio Sildenafil citrate Pulmonary arterial hypertension (WHO class II and III) List in a similar manner Complete
Revestive teduglutide Short Bowel Syndrome (SBS), pediatrics Reimburse with clinical criteria and/or conditions Complete
Revestive Teduglutide Short bowel syndrome Reimburse with clinical criteria and/or conditions Complete
Revlimid Lenalidomide Multiple Myeloma (+bortezomib+dex) Reimburse with clinical criteria and/or conditions Complete
Revlimid Lenalidomide Multiple Myeloma (as maintenance therapy) Reimburse with clinical criteria and/or conditions Complete
Revlimid Lenalidomide Multiple Myeloma, newly diagnosed Reimburse with clinical criteria and/or conditions Complete
Revolade Eltrombopag olamine Chronic immune thrombocytopenic purpura Do not list Complete
Revolade Eltrombopag Thrombocytopenia associated with chronic hepatitis c infection List with criteria/condition Complete
Revolade eltrombopag Severe aplastic anemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Rexulti Brexpiprazole schizophrenia Reimburse with clinical criteria and/or conditions Complete
Reyataz Atazanavir HIV infection List in a similar manner to other drugs in class Complete
Rezurock belumosudil Graft-versus-host disease Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Psoriatic Arthritis, adults Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib atopic dermatitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Crohns disease Reimburse with clinical criteria and/or conditions Complete
Rituxan Rituximab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Rituxan Rituximab Granulomatosis with polyangiitis and microscopic polyangiitis List with clinical criteria and/or conditions Complete
Rituxan Rituximab Acute Lymphoblastic Leukemia Do not reimburse Complete
Rosiver Ivermectin Rosacea List with criteria/condition Complete
Rozlytrek Entrectinib ROS1-positive NSCLC Reimburse with clinical criteria and/or conditions Complete